Modulation of aryl hydrocarbon receptor activity by four and a half LIM domain 2

International Journal of Biochemistry and Cell Biology

Volumn 41, Issue 5, 2009, Pages 1182-1188

  Kollara, Alexandra ^a,b   Brown, Theodore J ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Androgen receptor; Aryl hydrocarbon receptor; Aryl hydrocarbons; Four and a half LIM 2 protein; Nuclear receptor coactivator 4

Indexed keywords

ANDROGEN RECEPTOR; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450; FOUR AND A HALF LIM PROTEIN 2; NUCLEAR PROTEIN; NUCLEAR RECEPTOR COACTIVATOR 4; PROTEIN P160; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN COS1; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; REPORTER GENE; TRANSCRIPTION INITIATION;

ANIMALS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; CERCOPITHECUS AETHIOPS; COS CELLS; FEMALE; GENE EXPRESSION; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOPRECIPITATION; MICE; MUSCLE PROTEINS; RECEPTORS, ARYL HYDROCARBON; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 59649124441     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.10.019     Document Type: Article

References (55)

1. Beischlag T.V., Wang S., Rose D.W., Torchia J., Reisz-Porszasz S., Muhammad K., et al. Recruitment of the NCoA/SRC-1/p160 family of transcriptional coactivators by the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator complex. Mol Cell Biol 22 (2002) 4319-4333
2. Casper R.F., Quesne M., Rogers I.M., Shirota T., Jolivet A., Milgrom E., et al. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol 56 (1999) 784-790
3. Chan K.K., Tsui S.K., Lee S.M., Luk S.C., Liew C.C., Fung K.P., et al. Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart. Gene 210 (1998) 345-350
4. Denison M.S., Pandini A., Nagy S.R., Baldwin E.P., and Bonati L. Ligand binding and activation of the Ah receptor. Chem Biol Interact 141 (2002) 3-24
5. Dong X., Sweet J., Challis J.R., Brown T., and Lye S.J. Transcriptional activity of androgen receptor is modulated by two RNA splicing factors, PSF and p54nrb. Mol Cell Biol 27 (2007) 4863-4875
6. Du X., Hublitz P., Gunther T., Wilhelm D., Englert C., and Schule R. The LIM-only coactivator FHL2 modulates WT1 transcriptional activity during gonadal differentiation. Biochim Biophys Acta 1577 (2002) 93-101
7. Dye B.T., and Patton J.G. An RNA recognition motif (RRM) is required for the localization of PTB-associated splicing factor (PSF) to subnuclear speckles. Exp Cell Res 263 (2001) 131-144
8. Fan W., Yanase T., Morinaga H., Okabe T., Nomura M., Daitoku H., et al. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem 282 (2007) 7329-7338
9. Fritz W.A., Lin T.M., Cardiff R.D., and Peterson R.E. The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice. Carcinogenesis 28 (2007) 497-505
10. Gabriel B., Mildenberger S., Weisser C.W., Metzger E., Gitsch G., Schule R., et al. Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res 24 (2004) 921-927
11. Gu Y.Z., Hogenesch J.B., and Bradfield C.A. The PAS superfamily: sensors of environmental and developmental signals. Annu Rev Pharmacol Toxicol 40 (2000) 519-561
12. Hahn M.E. The aryl hydrocarbon receptor: a comparative perspective. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 121 (1998) 23-53
13. Hankinson O. The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 35 (1995) 307-340
14. Heinlein C.A., and Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 23 (2002) 175-200
15. Heinlein C.A., Ting H.J., Yeh S., and Chang C. Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma. J Biol Chem 274 (1999) 16147-16152
16. Heisler L.E., Evangelou A., Lew A.M., Trachtenberg J., Elsholtz H.P., and Brown T.J. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol 126 (1997) 59-73
17. Hengstler J.G., Van der Burg B., Steinberg P., and Oesch F. Interspecies differences in cancer susceptibility and toxicity. Drug Metab Rev 31 (1999) 917-970
18. Holcomb M., and Safe S. Inhibition of 7,12-dimethylbenzanthracene-induced rat mammary tumor growth by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Lett 82 (1994) 43-47
19. Jana N.R., Sarkar S., Ishizuka M., Yonemoto J., Tohyama C., and Sone H. Cross-talk between 2,3,7,8-tetrachlorodibenzo-p-dioxin and testosterone signal transduction pathways in LNCaP prostate cancer cells. Biochem Biophys Res Commun 256 (1999) 462-468
20. Johannessen M., Moller S., Hansen T., Moens U., and Van Ghelue M. The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell Mol Life Sci 63 (2006) 268-284
21. Kallio P.J., Poukka H., Moilanen A., Janne O.A., and Palvimo J.J. Androgen receptor-mediated transcriptional regulation in the absence of direct interaction with a specific DNA element. Mol Endocrinol 9 (1995) 1017-1028
22. Kang H.Y., Yeh S., Fujimoto N., and Chang C. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem 274 (1999) 8570-8576
23. Kashani M., Steiner G., Haitel A., Schaufler K., Thalhammer T., Amann G., et al. Expression of the aryl hydrocarbon receptor (AhR) and the aryl hydrocarbon receptor nuclear translocator (ARNT) in fetal, benign hyperplastic, and malignant prostate. Prostate 37 (1998) 98-108
24. Kawajiri K., and Fujii-Kuriyama Y. Cytochrome P450 gene regulation and physiological functions mediated by the aryl hydrocarbon receptor. Arch Biochem Biophys 464 (2007) 207-212
25. Kinoshita M., Nakagawa T., Shimizu A., and Katsuoka Y. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate. Int J Urol 12 (2005) 390-397
26. Kizu R., Okamura K., Toriba A., Kakishima H., Mizokami A., Burnstein K.L., et al. A role of aryl hydrocarbon receptor in the antiandrogenic effects of polycyclic aromatic hydrocarbons in LNCaP human prostate carcinoma cells. Arch Toxicol 77 (2003) 335-343
27. Kleiber K., Strebhardt K., and Martin B.T. The biological relevance of FHL2 in tumour cells and its role as a putative cancer target. Anticancer Res 27 (2007) 55-61
28. Kobayashi A., Numayama-Tsuruta K., Sogawa K., and Fujii-Kuriyama Y. CBP/p300 functions as a possible transcriptional coactivator of Ah receptor nuclear translocator (Arnt). J Biochem (Tokyo) 122 (1997) 703-710
29. Kociba R.J., Keyes D.G., Beyer J.E., Carreon R.M., Wade C.E., Dittenber D.A., et al. Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol Appl Pharmacol 46 (1978) 279-303
30. Kollara A., and Brown T.J. Functional interaction of nuclear receptor coactivator 4 with aryl hydrocarbon receptor. Biochem Biophys Res Commun 346 (2006) 526-534
31. Kumar M.B., Tarpey R.W., and Perdew G.H. Differential recruitment of coactivator RIP140 by Ah and estrogen receptors. Absence of a role for LXXLL motifs. J Biol Chem 274 (1999) 22155-22164
32. Labalette C., Renard C.A., Neuveut C., Buendia M.A., and Wei Y. Interaction and functional cooperation between the LIM protein FHL2, CBP/p300, and beta-catenin. Mol Cell Biol 24 (2004) 10689-10702
33. Martin B., Schneider R., Janetzky S., Waibler Z., Pandur P., Kuhl M., et al. The LIM-only protein FHL2 interacts with beta-catenin and promotes differentiation of mouse myoblasts. J Cell Biol 159 (2002) 113-122
34. Martin B.T., Kleiber K., Wixler V., Raab M., Zimmer B., Kaufmann M., et al. FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells. Cell Cycle 6 (2007) 1779-1788
35. Mimura J., and Fujii-Kuriyama Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim Biophys Acta 1619 (2003) 263-268
36. Mitchell S.H., Zhu W., and Young C.Y. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 59 (1999) 5892-5895
37. Morlon A., and Sassone-Corsi P. The LIM-only protein FHL2 is a serum-inducible transcriptional coactivator of AP-1. Proc Natl Acad Sci USA 100 (2003) 3977-3982
38. Morrow D., Qin C., Smith III R., and Safe S. Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation. J Steroid Biochem Mol Biol 88 (2004) 27-36
39. Muller J.M., Isele U., Metzger E., Rempel A., Moser M., Pscherer A., et al. FHL2, a novel tissue-specific coactivator of the androgen receptor. Embo J 19 (2000) 359-369
40. Nessler-Menardi C., Jotova I., Culig Z., Eder I.E., Putz T., Bartsch G., et al. Expression of androgen receptor coregulatory proteins in prostate cancer and stromal-cell culture models. Prostate 45 (2000) 124-131
41. Nguyen T.A., Hoivik D., Lee J.E., and Safe S. Interactions of nuclear receptor coactivator/corepressor proteins with the aryl hydrocarbon receptor complex. Arch Biochem Biophys 367 (1999) 250-257
42. Park J.J., Irvine R.A., Buchanan G., Koh S.S., Park J.M., Tilley W.D., et al. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res 60 (2000) 5946-5949
43. Petrulis J.R., and Perdew G.H. The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem Biol Interact 141 (2002) 25-40
44. Rushing S.R., and Denison M.S. The silencing mediator of retinoic acid and thyroid hormone receptors can interact with the aryl hydrocarbon (Ah) receptor but fails to repress Ah receptor-dependent gene expression. Arch Biochem Biophys 403 (2002) 189-201
45. Sambrook J., and Russell D.W. Molecular cloning: a laboratory manual (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
46. Schaufler K., Haslmayer P., Jager W., Pec M., and Thalhammer T. The environmental toxin 2,3,7,8-tetrachlorodibenzo-p-dioxin induces cytochrome P450 activity in high passage PC 3 and DU 145 human prostate cancer cell lines. Int J Mol Med 9 (2002) 411-416
47. Spink D.C., Spink B.C., Cao J.Q., DePasquale J.A., Pentecost B.T., Fasco M.J., et al. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 19 (1998) 291-298
48. Truica C.I., Byers S., and Gelmann E.P. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60 (2000) 4709-4713
49. Wang X., Thomsen J.S., Santostefano M., Rosengren R., Safe S., and Perdew G.H. Comparative properties of the nuclear aryl hydrocarbon (Ah) receptor complex from several human cell lines. Eur J Pharmacol 293 (1995) 191-205
50. Wei Y., Renard C.A., Labalette C., Wu Y., Levy L., Neuveut C., et al. Identification of the LIM protein FHL2 as a coactivator of beta-catenin. J Biol Chem 278 (2003) 5188-5194
51. Whitlock Jr. J.P. Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 39 (1999) 103-125
52. Yan J., Zhu J., Zhong H., Lu Q., Huang C., and Ye Q. BRCA1 interacts with FHL2 and enhances FHL2 transactivation function. FEBS Lett 553 (2003) 183-189
53. Yang Y., Hou H., Haller E.M., Nicosia S.V., and Bai W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. Embo J 24 (2005) 1021-1032
54. Yeh S., Hu Y.C., Rahman M., Lin H.K., Hsu C.L., Ting H.J., et al. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc Natl Acad Sci USA 97 (2000) 11256-11261
55. Yeh S., Miyamoto H., Nishimura K., Kang H., Ludlow J., Hsiao P., et al. Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. Biochem Biophys Res Commun 248 (1998) 361-367